Orum describes its therapy dubbed ORM6151 as an antibody enabled protein degrader merging the concept of an antibody drug conjugate with the field of protein degradation. Orum said it has received Food and Drug Administration clearance to enter Phase 1 testing in acute myeloid leukemia and myelodysplastic syndromes